Discovery of BKM120, a pan class I PI3 kinase inhibitor in phase I/II clinical trials

被引：0

作者：

Burger, Matthew T. ^{[1
]}

Pecchi, Sabina ^{[1
]}

Wagman, Allan ^{[1
]}

Ni, Zhi-Jie ^{[1
]}

Knapp, Mark ^{[1
]}

Atallah, Gordana ^{[1
]}

Pfister, Keith ^{[1
]}

Ng, Simon ^{[1
]}

Smith, Aaron ^{[1
]}

Pick, Teresa ^{[1
]}

Frazier, Kelly ^{[1
]}

Verhagen, Joelle ^{[1
]}

Zhang, Yanchen ^{[1
]}

Bartulis, Sarah ^{[1
]}

Hendricksen, Tom ^{[1
]}

Iwanowicz, Edwin ^{[1
]}

Hazenadar, Joshua ^{[1
]}

Huh, Kay ^{[1
]}

Ashash, Ahmad ^{[1
]}

Xin, Xiaohua ^{[1
]}

Menezes, Daniel ^{[1
]}

Merritt, Hanne ^{[1
]}

Wiesmann, Marion ^{[1
]}

Voliva, Charles ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, Emeryville, CA USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2010年 / 240卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

489-MEDI

引用

页数：1

共 50 条

[1] Phase 2 study of the pan-isoform PI3 kinase inhibitor BKM120 in metastatic urothelial carcinoma patients.
Iyer, Gopa
Tully, Christopher Michael
Garcia-Grossman, Ilana Rebecca
Scott, Sasinya N.
Boyd, Mariel Elena
Mccoy, Asia S.
Berger, Michael F.
Al-Ahmadie, Hikmat
Solit, David B.
Rosenberg, Jonathan E.
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[2] Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC)
Saura, C.
Burris, H.
Arteaga, C. L.
Mayer, I.
Germa, C.
Fretault, N.
Sternberg, D.
Trandafir, L.
Massacesi, C.
Rodon, J.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : S96 - S96
[3] Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Bendell, Johanna C.
Rodon, Jordi
Burris, Howard A.
de Jonge, Maja
Verweij, Jaap
Birle, Diana
Demanse, David
De Buck, Stefan S.
Ru, Qinhua C.
Peters, Malte
Goldbrunner, Michael
Baselga, Jose
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 282 - 290
[4] Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).
Armstrong, Andrew J.
Halabi, Susan
Healy, Patrick
Alumkal, Joshi J.
Yu, Evan Y.
Winters, Carolyn
Hobbs, Carey
Soleau, Colleen
Slottke, Rachel
Mundy, Kelly
George, Daniel J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[5] THE PAN-CLASS I PI3 KINASE INHIBITOR, NVP-BKM120, DEMONSTRATES ANTI-LEUKEMIC ACTIVITY IN ACUTE MYELOID LEUKEMIA
Allegretti, M.
Ricciardi, M. R.
Licchetta, R.
Mirabilii, S.
Orecchioni, S.
Reggiani, F.
Talarico, G.
Foa, R.
Bertolini, F.
Amadori, S.
Tafuri, A.
HAEMATOLOGICA, 2015, 100 : 211 - 211
[6] A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors
Baselga, J.
De Jonge, M. J.
Rodon, J.
Burris, H. A., III
Birle, D. C.
De Buck, S. S.
Demanse, D.
Ru, Q. C.
Goldbrunner, M.
Bendell, J. C.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[7] Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Burger, Matthew T.
Pecchi, Sabina
Wagman, Allan
Ni, Zhi-Jie
Knapp, Mark
Hendrickson, Thomas
Atallah, Gordana
Pfister, Keith
Zhang, Yanchen
Bartulis, Sarah
Frazier, Kelly
Ng, Simon
Smith, Aaron
Verhagen, Joelle
Haznedar, Joshua
Huh, Kay
Iwanowicz, Ed
Xin, Xiaohua
Menezes, Daniel
Merritt, Hanne
Lee, Isabelle
Wiesmann, Marion
Kaufman, Susan
Crawford, Kenneth
Chin, Michael
Bussiere, Dirksen
Shoemaker, Kevin
Zaror, Isabel
Maira, Sauveur-Michel
Voliva, Charles F.
ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (10): : 774 - 779
[8] Phase I dose- escalation study of buparlisib ( BKM120), an oral pan- class I PI3K inhibitor, in Japanese patients with advanced solid tumors
Ando, Yuichi
Inada-Inoue, Megumi
Mitsuma, Ayako
Yoshino, Takayuki
Ohtsu, Atsushi
Suenaga, Naoko
Sato, Masahiko
Kakizume, Tomoyuki
Robson, Matthew
Quadt, Cornelia
Doi, Toshihiko
CANCER SCIENCE, 2014, 105 (03) : 347 - 353
[9] Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Rodon, Jordi
Brana, Irene
Siu, Lillian L.
De Jonge, Maja J.
Homji, Natasha
Mills, David
Di Tomaso, Emmanuelle
Sarr, Celine
Trandafir, Lucia
Massacesi, Cristian
Eskens, Ferry
Bendell, Johanna C.
INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 670 - 681
[10] Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Jordi Rodon
Irene Braña
Lillian L Siu
Maja J De Jonge
Natasha Homji
David Mills
Emmanuelle Di Tomaso
Celine Sarr
Lucia Trandafir
Cristian Massacesi
Ferry Eskens
Johanna C Bendell
Investigational New Drugs, 2014, 32 : 670 - 681

← 1 2 3 4 5 →